BMO Capital Upgrades Biogen (BIIB) to Outperform StreetInsider.com (subscription) "With additional opportunities over the next 12 months for proof-of- concept with anti-LINGO for remyelination, TYSABRI in secondary progressive MS (SPMS), daclizumab in relapsing and remitting MS (RRMS), BIIB037 in Alzheimer's, STX-100 in idiopathic ... |
